Atrial fibrillation (Afib) has been declared epidemic on the rise in our aging population. It is estimated that roughly one quarter of now middle-aged men and women will develop Afib during their lifespan \[[@CIT0001], [@CIT0002]\]. The residual risk of stroke in anticoagulated patients as calculated by the CHA~2~DS~2~-VASc score ranges from 1.3% per year for a score of 1 to 15.2% per year for a score of 9 depending on the presence of clearly defined risk factors \[[@CIT0003]\]. Cardioembolic strokes are associated with adverse prognosis as depicted by a high rate of serious disability and mortality. The adverse prognosis may be attributable to relatively large clots that obstruct significant parts of the cerebral circulation as well as the characteristics of the affected population, which is mostly elderly, fragile, and often burdened with concomitant diseases. Thus, the need for safe and effective measures of stroke prevention in Afib patients is beyond doubt.

There is a large body of evidence demonstrating that therapy with vitamin K antagonists (VKA) reduces the risk of stroke in Afib patients roughly by 64% and ischemic stroke by 67% \[[@CIT0004]\]. Furthermore, as shown in a meta-analysis by Ruff *et al*. published in 2013 in The Lancet, high-dose novel oral anticoagulants (NOAC) are even more effective as compared to VKA in preventing ischemic strokes/systemic embolism with RR 0.81, 95% CI 0.73--0.91, which translates to 147 patients that need to be treated with a NOAC instead of VKA to prevent one additional embolic event \[[@CIT0005]\]. It is important to note, however, that low-dose NOAC prevented fewer ischemic strokes as compared to warfarin so only high-dose NOAC are associated with better outcomes. Consequently, European guidelines recommend that every patient with a CHA~2~DS~2~-VASc score of 1 or more (i.e. most of the Afib population) be treated with oral anticoagulants for stroke prevention with the preference of NOAC \[[@CIT0006]\].

There are two well-known downsides to oral anticoagulation, namely bleeding and compliance.

The risk of bleeding on oral anticoagulants (OAC) as depicted by the HAS-BLED score ranges from less than 2% per year to more than 4% per year depending on the presence of a number of risk factors \[[@CIT0007]\]. There are data showing that in patients with a HAS-BLED score above 3 the risk of hemorrhagic events exceeds that of thrombotic events \[[@CIT0008]\]. Furthermore, in patients with unstable international normalized ratio (INR) values during treatment with VKA the risk of bleeding increases significantly and is accompanied by a drop in treatment effectiveness \[[@CIT0009]\]. With NOAC, one does not need to adjust drug dosage to any biochemical parameters of coagulation. Furthermore, NOAC have been said to be safer than VKA in terms of bleeding complications. Indeed, as shown by Ruff\'s meta-analysis the rate of the most catastrophic complication, i.e. hemorrhagic stroke, is significantly reduced (RR 0.49, 95% CI 0.38--064) but with its relatively low incidence 219 patients need to be treated to prevent one such event \[[@CIT0005]\]. In fact, NOAC do not reduce major bleeding as compared to VKA and the frequency of gastrointestinal bleeding is even increased (RR 1.25, 95% CI 1.01--1.55).

For oral anticoagulation to be effective, it needs to be applied regularly and long-term. There are several reasons for non-compliance. The most obvious ones include bleeding complications, problematic INR control in the case of VKA, costs in the case of NOAC, and still too low awareness among both patients and medical professionals. Even in such a restrictively controlled environment as that imposed by randomized clinical trials, after a mean 2 to 2.5 years of follow-up 16.6% to 25.3% of patients ceased to receive anticoagulation, with similar numbers in NOAC and warfarin arms. The 10% per year dropout rate is far too high to be acceptable. The dropout curve may become more level during follow-up of patients who continue to receive the drug after 2 years, but there are real life data showing that after VKA treatment is initiated only about 30% of patients who started the treatment are still anticoagulated after 6 years follow-up \[[@CIT0010], [@CIT0011]\].

To sum up, even with the most state-of-the art pharmacological methods stroke prevention in Afib patients remains a significant challenge for contemporary medicine.

The rationale for mechanical closure of the left atrial appendage (LAAC) as a method of cardioembolic stroke prevention in Afib patients has been derived from pathophysiological reasoning and clinical observations. Atrial fibrillation disturbs the physiology of atrial blood flow in its passage from the pulmonary circulation to the left ventricle, leading to blood swirling and stasis within the left atrium and especially within its appendage, creating conditions for blood clotting. Indeed, clinical observations show 91% of left atrial thrombi to be located in its appendage \[[@CIT0012]\]. Hence, mechanically sealing off the appendage from the blood circulation was hypothesized to reduce the risk of clot formation and consequently incidence of ischemic stroke.

Given its location, irregular and highly variable shape, as well as fragile walls, development of suitable, effective, and safe technology to close the appendage as well as the procedure itself has not been straightforward. The first device for percutaneous LAAC was the PLAATO system \[[@CIT0013]\]. The first LAAC procedures in Poland were carried out with the use of PLAATO in the Institute of Cardiology in Warsaw by W. Rużyłło and A. Witkowski in May 2004. Out of the first 6 procedures the left atrial appendage (LAA) was successfully occluded in 5 cases and one procedure was abandoned due to unusual LAA anatomy. There were no periprocedural complications and at mean 54 months follow-up there were no ischemic strokes and no intracranial or gastrointestinal bleeding \[[@CIT0014]\]. Despite promising preliminary results the PLAATO system was withdrawn from the market in 2006 \[[@CIT0015]\]. Initial experience with PLAATO paved the way to new designs that are CE marked and currently in clinical use in Europe, i.e. the WATCHMAN device and the Amplatzer Cardiac Plug (ACP) device. The WATCHMAN device is based on a self-expanding nitinol cage covered with polyethylene membrane and equipped with barbs anchoring the device in the LAA. The ACP device consists of three self-expanding nitinol parts: a distal lobe with hooks filling the proximal part of the LAA, a connecting waist, and a proximal disk covering the ostium of the LAA for better stability and compete sealing of the appendage. Both devices are delivered transvenously via transseptal puncture using dedicated delivery systems. After implantation of such a device within weeks it becomes covered by endothelium and thus completely separates the appendage from the circulating blood. Apart from the two CE marked devices there are other technologies under development. One of those technologies, the LARIAT suture device has undergone preliminary clinical testing with promising results \[[@CIT0016]\]. The Lariat requires both transseptal and epicardial access for delivery of a suture that is tightened over the external side of the LAA ostium.

The only randomized data on LAAC come from the WATCHMAN device. In the PROTECT AF clinical randomized trial the device proved noninferior to warfarin in reducing the risk of stroke, systemic embolization, and cardiovascular death (RR 0.62, 95% CI 0.35--1.25). At the early phases of clinical experience with the device implantation procedural complications such as serious pericardial effusion (4.8%), procedure-related stroke (1.1%), and device embolization (0.6%) were noted \[[@CIT0017]\]. As discussed above, the procedure is technically demanding and a steep learning curve has been observed. Thus, the number of periprocedural complications consequently decreased along with increasing experience with device implantation during the PROTECT AF trial and decreased further in the Continuous Access Protocol, where the pericardial effusion rate dropped to 2.2%, with no reported periprocedural strokes \[[@CIT0018]\]. Similarly, the device implantation success rate increased from 90.1% in the PROTECT AF to 95% in the Continuous Access Protocol. The safety of implantation and clinical efficacy of the device have been further corroborated in the PREVAIL trial, the results of which were made public before the American College of Cardiology Scientific Sessions in 2013 \[[@CIT0019]\]. Thus, in its most recent vote an FDA advisory panel almost unanimously recommended the WATCHMAN device as a safe and effective method of stroke risk reduction in patients with Afib.

The design of the ACP device is based on broad clinical experience with other members of the Amplatzer family of cardiovascular plugs and occluders. The published data on safety and efficacy of the ACP device are based on prospective registries and case series. The largest early European prospective registry showed a high implantation success rate (96%) while major complications occurred in 7% of patients, similarly to early experience with the WATCHMAN device \[[@CIT0020]\]. Encouraging early experience has also been reported based on a Polish case series from the Institute of Cardiology in Warsaw and more recently from the Silesian Centre for Heart Diseases in Zabrze \[[@CIT0021], [@CIT0022]\].

In the recent European Society of Cardiology update to guidelines on atrial fibrillation, LAAC has been indicated for patients with high risk of stroke and contraindications for oral anticoagulation \[[@CIT0023]\]. The recommendation is very cautious (IIb), based mainly on the only available clinical trial with safety concerns that have already been discussed herein. Interestingly, the PROTECT AF trial did not enroll patients with contraindications to OAC. The target populations that could derive significant benefit from LAAC remain to be defined. At this point we can only hypothesize that apart from those who cannot be treated with OAC, patients with vascular disease requiring long-term antiplatelet therapy, patients who experience cardioembolic complications while on OAC, and patients with oncological problems or renal failure may also derive significant benefit from percutaneous LAA elimination.

Yet another unresolved issue is the most optimal therapy after the successful procedure. It remains to be tested which patient subgroups require long-term OAC despite LAAC and which are candidates for short-term dual antiplatelet or short-term OAC therapy and if life-long therapy with low-dose aspirin would be necessary afterwards.

In the face of the rapidly growing number of patients at risk of cardioembolic stroke associated with atrial fibrillation as well as limited compliance and risk of bleeding complications with currently available pharmacological preventive methods, there is no doubt that alternative methods of stroke prevention in Afib patients are needed. Percutaneous closure of the left atrial appendage is out of its infancy period and into adolescence. WATCHMAN and ACP devices are already available for clinical use while other designs are in the pipeline. The currently available data look very promising and with the national reimbursement programs for LAAC which are now in effect also in Poland we have the opportunity to observe the safety and effectiveness of the procedure in our daily clinical practice and look forward to real life data from individual centers and national registries. A broader spectrum of available evidence will help define patient subgroups who benefit the most from the procedure as well as better tailor the optimal treatment regimens after device implantation.
